Hemostasis

Johnson & Johnson Invests in Chinese Biotech Firm

The company’s Johnson & Johnson (China) Investment division has acquired Guangzhou Bioseal Biotechnology to bolster its hemostasis product portfolio.

Johnson & Johnson (China) Investment Ltd. today announced it has acquired Guangzhou Bioseal Biotechnology Co., Ltd. (Bioseal) a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery. The acquisition was completed after obtaining all necessary Chinese Government approvals. Financial terms of the transaction are not being disclosed.

No votes yet
Syndicate content